Tubeimoside I Suppresses Diabetes-induced Bone Loss in Rats, Osteoclast Formation, and RANKL-induced Nuclear Factor-κB Pathway
Overview
Pharmacology
Affiliations
Type 2 diabetes mellitus is often companied with osteoporosis, a process which involves osteoclast activation. In this study, we found tubeimoside I, a natural compound isolated from the Chinese medicinal herb Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae), significantly ameliorated the decrease of bone mass in type 2 diabetes-induced osteoporosis in rats. It appears that tubeimoside I exerts this protecting effect through inhibiting osteoclast formation and function. Futhermore, our study showed that tubeimoside I inhibits NF-κB transcriptional activation and degradation of IκBα. Collectively, our results reveal that tubeimoside I attenuates osteoclastogenesis through down-regulating NF-κB signaling pathway, and is a potential candidate for the treatment of bone-destructive diseases like type 2 diabetic osteoporosis.
Liu F, Liao B, Ling Y, Meng X, Wang J, Hu L Int J Immunopathol Pharmacol. 2024; 38:3946320241279525.
PMID: 39180223 PMC: 11344256. DOI: 10.1177/03946320241279525.
Hu D, Cui L, Zhang S, He S, Zhuo Y, Li D Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(6):4069-4087.
PMID: 38010398 DOI: 10.1007/s00210-023-02855-1.
Chinese endemic medicinal plant (Maxim.) Franquet: A comprehensive review.
Zhou Y, Liu J, Zhang J, Xu Y, Li W, Gao P Front Pharmacol. 2022; 13:974054.
PMID: 36160391 PMC: 9490187. DOI: 10.3389/fphar.2022.974054.
Zhuo Y, Li M, Jiang Q, Ke H, Liang Q, Zeng L Front Endocrinol (Lausanne). 2022; 13:901545.
PMID: 35651977 PMC: 9150774. DOI: 10.3389/fendo.2022.901545.
Challenges to Improve Bone Healing Under Diabetic Conditions.
Chen Y, Zhou Y, Lin J, Zhang S Front Endocrinol (Lausanne). 2022; 13:861878.
PMID: 35418946 PMC: 8996179. DOI: 10.3389/fendo.2022.861878.